adagloxad simolenin
Vaccineexperimental
Clinical trial activity
8 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT00857545)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Immunotherapy · Phase 1
- Lung Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 3
Mechanism of action
- Hemocyanin 1VACCINE ANTIGEN
Hemocyanin 1 vaccine antigen
- GlobohexaosylceramideVACCINE ANTIGEN
Globohexaosylceramide vaccine antigen
Cancer vaccine targeting Globo H
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707279 ↗
Also known as
- adagloxad simolenin combined with obi-821
- obi-821
- opt-822
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06490198 | Phase 1 | Jul 31, 2024 | Chang Gung University |
| NCT05442060 | Phase 2 | Jul 27, 2022 | OBI Pharma, Inc |
| NCT05376423 | Phase 2 | Jun 2, 2022 | National Taiwan University |
| NCT03562637 | Phase 3 | Oct 19, 2018 | OBI Pharma, Inc |
| NCT03608878 | Phase 2 | Sep 1, 2018 | Chang Gung University |
| NCT02310464 | Phase 1 | Dec 1, 2015 | Gabrail Cancer Center, Mary Crowley Cancer Center, National Taiwan University, OBI Pharma, Inc, Taipei Medical University |
| NCT02132988 | Phase 2 | Nov 1, 2013 | Mackay Medical College, OBI Pharma, Inc |
| NCT00857545 | Phase 2 | Jul 1, 2010 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OBI Pharma, Inc | For profit | 4 | 3 | 3 | 2013 |
| Chang Gung University | Academic/Hospital | 2 | 2 | 2 | 2018 |
| National Taiwan University | Academic/Hospital | 2 | 1 | 2 | 2015 |
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Mackay Medical College | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Mary Crowley Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2015 |
10 organizations
Page 1 / 1